desk
Share
News Topical, Digital Desk : Brokerage houses have released fresh reports on several major stocks and sectors. Nomura has expressed confidence in M&M (Mahindra & Mahindra), while Jefferies has called UltraTech Cement a long-term player. Citi and UBS have given their outlook on Billionbrains (Grow). Anthem Bio has also received positive feedback. HSBC has given important signals on Godrej Properties and the metal sector. These reports are considered important for investors.
Nomura is confident in M&M
- Nomura has a buy call on M&M with a target price of ₹4,662 per share. According to the brokerage, SML's fourth-quarter results showed strong volumes, but rising costs pressured gross margins.
- The report states that price hikes could lead to margin recovery in fiscal 2027. The company is targeting a 10-12% market share in the medium term through new segments, with ICV entry being key.
- Additionally, plans are underway to expand its AC bus, ambulance, and commercial vehicle portfolio. An e-bus rollout in fiscal 2027 could also strengthen the company's position in the EV segment.
Jefferies remains confident in UltraTech
- Jefferies has given a buy call on UltraTech Cement and has a target of Rs 14,025.
- According to the brokerage, with a capacity of 200 MTPA, the company is now the world's largest cement company outside China. The company is growing steadily through organic expansion and a disciplined acquisition strategy.
- The report said that high utilization, nearly 30% market share, and the best EBITDA margins in the industry make it a strong asset. While the valuation is premium, it remains a strong bet on the infrastructure theme over the long term.
Citi and UBS's opinion on Groww
- Citi has given a buy call on Billionbrains (Groww) with a target price of Rs 230.
- According to the brokerage, the fourth quarter was strong. Core PBT grew 27% quarter-on-quarter, beating expectations. Market volatility is driving trading volume and activity.
- The company is expanding its MTF and new products. While near-term momentum may be limited, its long-term positioning is strong.
- Meanwhile, UBS has a neutral call on the stock and a target price of ₹210. UBS says growth is coming from operating leverage and market share gains. Strong engagement metrics and a wealth platform could further support the stock.
Citi Bullish on Anthem Bios
- Citi has given a buy call on Anthem Bio and has a target of Rs 870.
- According to the brokerage, it is among the fastest-growing CRDMO companies. Its strengths include a strong commercial molecule mix, client stickiness, and diverse platform capabilities.
- Citi has projected a revenue CAGR of 26 per cent between FY23 and FY26.
HSBC has a buy call on Godrej Properties with a target price of ₹2,800. The brokerage estimates pre-sales growth in fiscal 2027 at around 20%, supported by a strong project pipeline. The company is expected to become free cash flow positive from fiscal 2027, with dividends also expected.
What did it say about the metals sector?
HSBC said that higher energy costs pose a risk of weakening demand in the second half. The full burden of these costs has not yet been passed on to customers. However, slower steel exports and production in China could be supportive for India. A stable coal premium could help domestic companies protect margins.
What should investors understand?
Brokerage reports clearly indicate that the market is focused on strong balance sheets, growth visibility, and sector leaders. Selective opportunities are visible in auto, cement, and real estate, while caution is warranted in the metals sector.
--Advertisement--
